Aurora Cannabis (TSX:ACB): Why You Should Avoid This Pot Stock

Aurora Cannabis (TSX:ACB)(NYSE:ACB) stock has lost about half of its value year-to-date, but it’s still not a good buy on the dip.

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Although Aurora Cannabis (TSX:ACB)(NYSE:ACB) is one of the most popular pot stocks among young investors, there are better plays in the marijuana sector now.

The pot producer seemed to be on the right path last year

At that time last year, Aurora Cannabis seemed to be on the way to success. It had completed more than a dozen acquisitions and was to lead Canada with more than 650,000 kilograms of peak annual production. Aurora also had access to two dozen markets outside of the country.

But Aurora’s dreams were shattered by regulatory-based supply issues in the Canadian market, as well as by its own poor risk management and balance sheet.

One of Aurora’s biggest problems is that its acquisition-oriented approach has left it in a cash bind. Despite stopping construction of two of its largest projects, the sale of a one million square foot greenhouse, the layoff of 500 workers and the commitment to reduce its sales, general and administrative (SG&A) expenses by at least 55% in just three quarters, there is still no guarantee that Aurora will comply with its new debt covenant or achieve operating profitability.

In fact, the only way Aurora can generate cash now is by selling its common stock. Aurora rolled up its shares in May to give investors a share for 12 after the New York Stock Exchange warned that it could be delisted after its average share price fell below a dollar for 30 consecutive trading days. The number of Aurora shares has increased from approximately 1 million to 110 million since June 30, 2014.

Aurora surged in May on strong sales

Aurora Cannabis stock surged in May after the company announced better-than-expected quarterly sales. Revenues jumped 18% from the previous quarter due to strong demand for their line of consumer products. But the pot producer lost more money than expected.

Despite writing down more than $1 billion in goodwill just two quarters ago, Aurora still carries $2.4 billion on its balance sheet, which represents more than half of the total assets of the company.

Aurora Cannabis stock also increased in May after the company announced it was entering the U.S. retail CBD market with the acquisition of hemp-based cannabidiol company Reliva LLC.

But shares have lost a third of their value since May 21. The pot producer announced in June that co-founder Steve Dobler step down as president and director at the end of the month. Co-founder and CEO Terry Booth retired from the company’s board of directors at the end of June.

The company still hasn’t announced a new permanent CEO. The longer it takes, the more the stock might drop. In addition, who Aurora chooses as CEO is important because if the market is unhappy with the hiring, this highly anticipated news could ultimately drive a decline in the stock.

Aurora is a risky bet

Aurora plans to close five facilities, lay off approximately 700 workers, and anticipates a $60 million charge in the next quarter. The moves are part of its business transformation plan announced in February.

Aurora’s risk/reward is still not good enough to make it a buy, however. Earnings are expected to fall by 291% this year to -$13.62 a share. That’s a huge loss. In 2021, the pot company’s situation should improve. Earnings are expected to grow by 91% to a loss of 1.30 per share.

As Aurora stock will likely continue to fall in 2020 on poor results, it’s better to avoid this pot stock.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Stephanie Bedard-Chateauneuf has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »